Seasonal vaccine approval is routine and expected after the EMA ETF recommendation. Monitor EU member state procurement decisions and reimbursement terms for the 2026-2027 season to gauge revenue contribution. Also watch for FDA and other regulatory decisions on the updated formula in other key markets.
Price Chart
Executive Summary
BioNTech (BNTX) announced via 6-K that the European Commission has granted marketing authorization for its 2026-2027 COVID-19 vaccine formula targeting the XFG variant. The approval, valid across the EU plus Iceland, Liechtenstein, and Norway, allows BioNTech and Pfizer to supply the updated monovalent vaccine ahead of the respiratory season. Manufacturing at risk has already commenced, but no financial terms or revenue impact were disclosed.
Key Facts
- European Commission authorized the 2026-2027 XFG-adapted COVID-19 vaccine for individuals 6 months and older.
- Authorization is valid in all 27 EU member states, Iceland, Liechtenstein, and Norway.
- Manufacturing at risk has been initiated by Pfizer and BioNTech to ensure supply readiness.
- More than 5 billion doses of the Pfizer-BioNTech COVID-19 vaccines have been distributed globally.
- No financial figures (revenue, deal value, or guidance) were provided in the filing.
Financial Impact
Regulatory approval for seasonal vaccine update; no financial terms or revenue figures disclosed.
Risk Factors
- Demand for COVID-19 vaccines may decline further as the pandemic transitions to endemic phase.
- Competition from other vaccine developers targeting the same variant could limit market share.
- Evolving viral variants may reduce efficacy of the XFG-adapted vaccine before the season ends.
- Pricing pressure from government procurement could compress margins.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000047 |
| Document: form6-kxfgvariantvaccineec.htm | 0001776985-26-000047 |
| Document: 0001776985-26-000047-index-headers.html | 0001776985-26-000047 |
| Document: 0001776985-26-000047-index.html | 0001776985-26-000047 |
| Document: 0001776985-26-000047.txt | 0001776985-26-000047 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.90 (−1.98%) |
Sep 14, 2026 18d ago | Press Release | $98.86 $98.00 | ▼ −0.87% | ▼ −0.98% | $96.90 (−1.98%) |
Aug 28, 2026 5w ago | 6-K | $102.08 $103.76 | ▼ −1.65% | ▼ −1.54% | $96.90 (+5.07%) |
Aug 20, 2026 6w ago | 6-K | $110.89 $111.40 | ▲ +0.46% | ▼ −0.65% | $96.90 (−12.62%) |
Aug 11, 2026 7w ago | Institutional Cluster | $92.80 $92.75 | ▼ −0.05% | ▲ +0.35% | $96.90 (+4.42%) |
Aug 4, 2026 8w ago | 6-K | $91.35 $92.80 | ▼ −1.59% | ▼ −1.69% | $96.90 (−6.08%) |
Aug 3, 2026 8w ago | 6-K | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.90 (+5.04%) |
Aug 3, 2026 8w ago | Press Release | $92.25 $92.80 | ▲ +0.60% | ▼ −1.43% | $96.90 (+5.04%) |
Jul 29, 2026 9w ago | 6-K | $92.85 $91.19 | ▼ −1.79% | ▼ −5.41% | $96.90 (+4.36%) |
Jun 8, 2026 16w ago | 6-K | $85.50 $90.80 | ▲ +6.20% | ▲ +4.09% | $96.90 (+13.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access